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Primary ciliary dyskinesia (PCD) is a genetically heteroge-
neous, autosomal recessive disorder caused by abnormal cili-
ary ultrastructure and function, characterized clinically by oto-





) have recently been described in PCD pa-
tients, with outer dynein arm (ODA) defects. The aims of the




 mutations in 13 PCD
patients with ODA defects (from 7 unrelated families) and to
assess genotype/phenotype correlations in patients and fam-





detected in three PCD patients from two families. The oppo-
site allele had the novel missense mutation G1874C (W568S)
in both affected individuals from one family, and a nonsense
mutation G1875A (W568X) in an affected individual from an-
other family. The tryptophan at position 568 is a highly con-
served residue in the WD-repeat region, and a mutation is
predicted to lead to abnormal folding of the protein and loss
of function. None of these mutations were found in 32 other




 are causative for PCD with ODA defects, and are likely
the genetic origin of clinical disease in some PCD patients
with ultrastructural defects in the ODA.
 
Primary ciliary dyskinesia (PCD) is a genetically heteroge-
neous disorder, characterized by chronic middle ear, sinus,
and lung disease (1, 2). The disease is usually inherited as





1 in 15,000–30,000 (3). Approximately
50% of the patients with PCD have situs inversus (SI), in-
dicating that there is a tight (but random) association be-
tween SI and PCD, termed Kartagener’s syndrome (4, 5).
The pathogenesis of the disease reflects defective epi-
thelial ciliary structure and function in the eustachian
tube, sinuses, and lower airways, leading to abnormal mu-
cociliary clearance, an important component of host de-
fenses in these organ systems (6, 7). A variety of ultra-
structural abnormalities of cilia have been described. Since
the ciliary axoneme is comprised of nearly 250 polypep-
tides, there are many candidate genes that could account
for the genetic heterogeneity of PCD. The most common
form of PCD is associated with defects (or absence) of the
outer dynein arm (ODA), inner dynein arm (IDA), or
both dynein arms (6, 8). Components of dynein arms in-
clude axonemal dyneins, which are large globular microtu-
bule-activated ATPase motor protein complexes com-
posed of several heavy, intermediate, and light chains.
Recently, a human intermediate chain dynein 1 (DNAI1)





 IC78 gene, was cloned, and loss-of-function
mutations were described in the DNAI1 gene in a PCD
patient with ciliary ODA defects (9). In the same study,
five other consanguineous families with defective ODA
did not show linkage to the DNAI1 gene when intragenic
single nucleotide polymorphisms (SNPs) were used, fur-
ther supporting the hypothesis that PCD is a genetically
heterogeneous disease.
Without careful categorization and phenotyping of
PCD patients, genetic heterogeneity is a significant limita-
tion for large-scale genetic testing. As part of an overall ef-
fort to study the phenotype and genetics of patients with
PCD, we have assembled a large database of well-charac-
terized PCD patients and family members. This effort in-
cludes the collection of clinical and physiologic data, in-
cluding measures of nasal nitric oxide (NO), development
of pedigrees, and analyses of ciliary structure and function.
Patients can be segregated into cohorts, depending on the
nature of the ciliary structural abnormality (inner versus
outer dynein arm versus other ciliary abnormality), which
facilitates genetic testing in a more selective and efficient
fashion (10). For the current study, we initially focused on




Patients: Clinical Evaluations and Ciliary Dynein 
Arm Evaluations
 
All patients with PCD, and their available family members, were
seen and evaluated at the General Clinical Research Center of
the University of North Carolina (UNC). Studies were per-
formed under the auspices of the Committee for the Protection
of the Rights of Human Subjects at UNC Chapel Hill. Clinical
evaluations included a detailed medical history (including an ex-
tended family history), physical examination, sinus and/or chest
radiographs (CXR), lung function testing, and sputum microbiol-
ogy. Specific information was sought for neonatal respiratory dis-
tress, recurrent otitis media with a requirement for placement of
drainage tubes, recurrent bronchitis and copious purulent spu-
tum production, and situs inversus (10). To assess ciliary struc-
ture, epithelial cells were obtained from the inferior turbinates
using a noninvasive nasal curettage technique (11). The speci-
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ness were obtained and post-stained with uranyl acetate and lead
citrate, and examined and photographed in a Zeiss EM900 oper-




50,000. Ciliary images were considered acceptable for analysis
based on criteria described elsewhere (12). Each subject was cat-
egorized as having a predominantly ODA defect, IDA defect,
both dynein arms defective, or other microtubular defects (cen-
tral pair abnormal, or radial spoke abnormalities). A defect was
defined as absence or near-absence (short or stubby on all sec-
tions) of dynein arms. Those family members unable to travel to
UNC for evaluation agreed to provide DNA by means of the
buccal brush method; evidence for PCD was sought in these sub-
jects by a careful history as described above.
A selected cohort of PCD patients with clear-cut defects in
ODA were chosen for the initial genetic study of the DNAI1
gene, because mutations in this gene appear to be associated with
PCD and ODA defects. This cohort included 13 PCD patients




 IDA defects), and, where
available, first-degree relatives from the seven families. Two fam-
ilies (Families 7 and 11) had known consanguinity, whereas there
was no known inbreeding in the other five families. This strategy
allowed us to use intragenic SNPs in the DNAI1 gene in these
families to exclude the ones where linkage to DNAI1 gene could




As an additional phenotypic marker, we measured nasal NO in
all subjects with PCD. Recent reports suggest that nasal NO is
low in PCD patients, and effectively distinguishes between PCD
and normal subjects, although the precise nature of the link be-
tween the observation and the molecular abnormality causing
PCD remains unknown (13, 14). No subjects had acute nasal dis-
ease (infection/inflammation) at the time of measurement, and
none were smokers. NO levels were measured with the velum
(soft palate) voluntarily closed, at a constant sampling rate of
460–500 ml/min, channeled directly into a Sievers Model 270
chemiluminescent analyzer (Sievers, Boulder, CO). For each in-
dividual, the level of NO reported is derived from four readings
(two per nostril), and reported as the product of steady state (pla-
teau) NO concentration and nasal flow (expressed as nL/min).
Nasal NO levels were also measured in a control group of nonal-








 16, mean age

















DNA was acquired from all subjects from either fresh whole
blood or from buccal cell brushings. Genomic DNA extraction
from blood was performed using standard protocol (15). QIAamp
DNA mini kit (Qiagen, Valencia, CA) was used to extract genomic




Two previously reported intragenic SNPs at nucleotide 1003 of
exon 11 and nucleotide 42 of intron 11 (9) and one in intron 14
(B. Duriez, personal communication) were used to test for link-
age of PCD to DNAI1 gene. Intronic primer sequences were
those used by Pennarun and coworkers (9), unless otherwise
stated. Polymerase chain reaction (PCR) was performed to am-
plify the fragments with reagents and AmpliTaq DNA polymer-
ase (Perkin Elmer, Foster City, CA) using manufacturer’s in-




C for 5 min


















C. Direct DNA sequencing of PCR product was
performed on ABI 310 automated DNA sequencer (PE Biosys-
tems, Foster City, CA) using Prism BigDye Primer Cycle Se-




All 20 exons of the DNAI1 gene were amplified and sequenced
using intronic primers of Pennarun and colleagues (9), except



















DNA from one patient with PCD from each of the families, not
excluded by the linkage studies, was completely sequenced to de-
tect the mutation(s) in the DNAI1 gene. After identification of
the mutations, the remaining family members were also tested





gestion for intron 1 or denaturing high performance liquid chroma-
tography (DHPLC) for codon 568 of exon 17. The flanking prim-
ers utilized to amplify exon/intron 1 were IC78-Ex1F (forward)









. PCR-amplification of exon 17 for DHPLC analyses was



















plex formation was performed as described earlier (16–18) using
the Helix System (Varian Inc., Palo Alto, CA); temperature for




C. Heterozygous profiles were de-
tected as distinct elution peaks from homozygous wild-type peaks.
After testing of the initial seven families was complete and
mutations were identified in DNAI1 gene, an additional 32 other
patients with PCD from 15 unrelated families with miscellaneous




mutations, using enzyme digestion assay or DHPLC as rapid screen-
Figure 1. Representative electron microscopic images of a cross-
section of a cilium. (A) Normal cilium from a clinically unaf-
fected sibling II-1 (Family 16) with both wild-type alleles for the
DNAI1 gene. “O” represents the outer dynein arm (open arrow)
and “I” represents the inner dynein arm (solid arrow). The cen-
tral doublets and radial spokes are also visible. (B, C, and D) Cil-
ium from PCD subjects III-1 (Family 5), III-3 (Family 5), and II-2
(Family 16), respectively, demonstrating absence of outer plus
abnormal inner dynein arms.
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ing tools. Linkage studies with DNAI1 gene were not performed in
these 32 patients. To estimate the frequency of mutations at codon
568 in the general population, 400 chromosomes from 200 non-PCD






Overall, we have characterized 45 patients from 22 unre-
lated families with clinical disease consistent with PCD
and defects of ciliary ultrastructure and function (10, 19).
From this population, we selected 13 patients with PCD (seven
male) with clear-cut defects in ODA (with or without IDA









jects in all), initially to test for linkage to the DNAI1 gene.
The 25 family members were evaluated in detail, and another
21 agreed to provide DNA using the buccal brush technique.
 
Clinical Evaluations of Patients with PCD and
ODA Defects
 
Table 1 depicts the 13 patients with PCD (mean age 20 yr;
range 3–44, six females) from the seven families. All had
clinical evidence of sino-pulmonary disease, chronic mid-
dle ear disease in childhood, and/or neonatal respiratory pul-
monary problems, consistent with clinical PCD. Five (three
males) had SI totalis. The mean forced expiratory volume




) (% predicted) was 80 (range 51–123), and
bronchiectasis was present on CXR and/or chest com-
puted tomography (CT) in 10 of 13 patients. The 13 pa-






























consistent with previously reported levels in PCD (10, 13).
These phenotypic data support the diagnosis of PCD in
these individuals, and the levels are similar to other PCD
patients with miscellaneous defects in DA (data not shown).
None of the family members evaluated, including the par-
ents and unaffected siblings of patients with PCD, had
clinical disease suggestive of the PCD phenotype, includ-












 14/15; one had changes consistent






7/8; one had evidence of mild unilateral maxillary mucosal


























All evaluated patients with PCD had qualitative defects in
the ODA. The ODA was absent in 8/13, and near-absent
in 5/13. The IDA was also absent in 3/13, near-absent in
6/13, and normal in 4/13. Figure 1 illustrates cross-sectional
images of cilia from the probands of two families (III-1
and III-3 from Family 5, and II-2 from Family 16) with
missing ODA, variably absent/abnormal IDA, compared
with a normal control image from a sibling with no clinical




In the seven families, there were a total of 59 subjects from
whom the DNA was available, of whom 14 were parents,
and 32 were first- or second-degree relatives (siblings, aunts,
uncles, or grandparents). To test the involvement of the
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were determined by direct genomic DNA sequencing. As
shown in Figure 2A, Family 7 was excluded from linkage
between the DNAI1 gene and the PCD phenotype, be-
cause two affected individuals (II-1 and II-3) and an unaf-
fected sister (II-2) shared the same genotype (TT) at in-
tron 11 locus. Family 18 was excluded from linkage because





type at polymorphic loci in intron 14 (data not shown).
Families 11 and 16 were partially informative (mothers in
both families were homozygous for SNPs) for intragenic
polymorphisms at nucleotide 1003 of exon 11 and nucle-
otide 42 of intron 11, respectively, since affected children





 Figure 2B for Family 11). In Family 8,
both affected siblings shared the same homozygous geno-
type for intron 11 SNP (father was heterozygous at this lo-
cus), but due to the unavailability of DNA from an unaf-
fected brother, linkage status could not be established
(data not shown); both the parents in this family were ho-
mozygous for the other polymorphisms. The remaining
two families (Families 3 and 5) were uninformative since










We completely sequenced the DNAI1 gene from one pa-
tient with PCD from each of the five families (3, 5, 8, 11,
16) in whom we could not exclude linkage between the
DNAI1 gene and the PCD phenotype (i.e., who were ei-
ther partially informative, or uninformative, for linkage).
Mutations in the DNAI1 gene were found in two families





3 position of intron 1 (219
 
3insT) in both
the families, as reported earlier (9), which can be detected
by the mutation-induced HpaI restriction site (Figure 3A).
Novel mutations on codon 568 were detected on the sec-
ond allele of both the families. Family 5 had the G1874C
transversion in exon 17 (missense mutation), designated as
W568S, and Family 16 had a G1875A transition in exon 17
(nonsense mutation), designated as W568X (Figure 3B).
Figures 3C and 4 depict the segregation of mutations in
both the families. There was no known consanguinity in ei-
ther family. The probands in Family 5 (III-1 and III-3) were
two male patients aged 3 and 6 yr, both with absent ODA.
Both patients were found to have 2193insT on one allele
and W568S on the opposite allele. The 2193insT was in-
Figure 2. Linkage analyses at exon/
intron 11 polymorphic loci in DNAI1
gene. (A) Both affected patients
(II-1 and II-3) and their unaffected
siblings (II-2) from Family 7 shared
the same genotype (TT) at intron
11 locus, hence the family was
excluded from linkage. (B) Both
affected individuals (II-2 and II-3)
from Family 11 shared the same
genotype (GG), whereas their un-
affected sibling (II-1) had a different genotype (GA) at exon 11
locus. Since the mother (I-2) was homozygous at the polymorphic
locus, this family was partially informative. (C) Family 3 was un-
informative, since both the parents were homozygous (GG) at
the exon 11 polymorphic locus.
Figure 3. Familial mutations in DNAI1 gene. (A) Segregation
analysis of the 1-bp insertion of T at 3 position of intron 1
(splice site mutation, 2193insT) in Family 16 identified by mu-
tation-induced cleavage at a HpaI site. A 284/285-bp region of
the DNAI gene was amplified using IC78-Ex1F and IC78-Ex1R
primers followed by restriction digestion with HpaI. PCR-prod-
uct from normal allele is not cut, whereas the mutant allele
cleaves into 222- and 63-bp fragments. Heterozygous individuals
presented with one uncut and another digested allele on 2.5%
agarose gel. From Family 16, the father (I-1) and his unaffected
daughter (II-1) are wild type; the mother (I-2) and an affected
son (II-2) are heterozygous. The mutation was confirmed by se-
quencing both the strands in all the individuals. Lane M corre-
sponds to 1-kb ladder from Promega and lane C corresponds to
control without DNA. (B) DHPLC (left panel) and sequence
analyses (right panel) to detect novel mutations at codon 568.
Mutations were detected by direct bidirectional sequencing of
PCR-amplified product of exon 17 with intronic primers (IC78-
Ex17F and IC78-Ex17R). DHPLC analyses at a run temperature
of 62C were compatible with the sequencing analyses. Distinct
elution peaks were obtained for heterozygous and homozygous
wild type (WT), which was analyzed visually (left panel). WT se-
quence at codon 568 from a control subject (top panel). A novel
paternal missense mutation in PCD patient III-3 from Family 5
was found, which was heterozygous 1874 G→C transversion and
was designated as “W568S” (middle panel). A novel paternal
nonsense mutation in PCD patient II-2 from Family 16 was also
found, which was heterozygous 1875 G→A transition and was
designated as “W568X” (bottom panel). (C) A novel nonsense
mutation (W568X) was found in an affected subject (II-2) from
Family 16, which was heterozygous for 1875 G→A transition in
exon 17. The maternal mutation in the affected individual is the
same previously reported splice mutation (2193insT). Neither
mutation was present in the unaffected sibling (II-1).
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herited from the mother (II-4) and was not present in the
unaffected sibling (III-2), who had normal ciliary ultra-
structure. This mutation was also present in the maternal
aunt and the maternal grandmother (II-6 and I-4, respec-
tively). The W568S mutation was present in the unaffected
sibling (III-2), the father (II-3), a paternal aunt (II-2), and
the paternal grandmother (I-2), all with normal ODA
(Figure 4). Both these mutations segregated only in af-
fected individuals in Family 5. In Family 16, a 45-yr-old
male (II-2) with PCD had the 2193insT mutation on one
allele, also present in the mother (I-2) (Figure 3C). A
W568X nonsense mutation was identified on the second
allele, which was inherited from the father (I-1). Both these
mutations segregated only in the affected individual; a clin-
ically normal female sibling (II-1), aged 50, did not carry
either mutation, and had normal ciliary ultrastructure.
To assess the allele frequency of codon 568 mutations
in the general population, we screened DNA from 200
anonymous individuals with hemophilia. The allele fre-
quency of the W568X nonsense mutation in these individ-
uals was 0.0025 (1 in 400 chromosomes analyzed), whereas
none of the 200 individuals (400 chromosomes) analyzed
harbored the W568S missense mutation. The splice site
(2193insT) mutation frequency was tested previously in
50 individuals (100 chromosomes) and none of them had
the mutation (9).
All additional 32 patients with PCD (from 15 families)
with miscellaneous ciliary defects were found to be wild
type when analyzed for codon 568 and 2193insT muta-
tions, presumably because of mutations in genes encoding
for other ciliary defects, or indeed mutations elsewhere in
the DNAI1 gene. This scenario is consistent with the ge-
netic heterogeneity associated with PCD (9).
Discussion
PCD is characterized by respiratory distress at birth, chronic
middle ear disease during childhood, chronic sinusitis, and
frequent respiratory infections leading to bronchiectasis in
later life (2). The differential diagnosis is broad and may
be confused (especially in children) with other causes of
chronic airways disease. Defining the genetics of PCD will
be useful for earlier and more definitive diagnosis, and in
the long term for the development of novel therapies. One
of the primary challenges for the study of PCD is the ge-
netic heterogeneity of the disorder.
To counter this limitation, we have characterized a large
number of patients with PCD in considerable detail, which
allows more rigorous categorization of the phenotype. Pa-
tients with PCD commonly have a history of neonatal re-
spiratory distress/pneumonia, recurrent otitis media, and
chronic cough (20). In addition, analyzing the ultrastruc-
tural defects is also discriminatory for PCD, with defects in
the ODA specifically seen in PCD. Although the precise
nature of the relationship between nasal NO levels and
PCD has not been elucidated, the initial reports of very
low nasal NO levels in patients with PCD are borne out in
the subjects with PCD in this report. Using this approach,
it is possible to better categorize patients, and to systemat-
ically test those subjects who have similar disease and/or
electron microscopic findings (ultrastructural defects in
cilia) for genetic mutations associated with PCD. Multiple
family members were also evaluated for clinical disease,
and the presence of mutations in the gene. No stigmata of
PCD were evident on evaluation or by history in those
subjects carrying one mutation in the DNAI1 gene, includ-
ing parents, sibling, grandparents, or aunts. One sibling
was clinically normal, and was not a carrier of any muta-
tion. Thus, carriers of loss-of-function mutations in the
DNAI1 gene do not appear, at least in this small sample,
to be predisposed to any discernable clinical disease.
The recent description of loss-of-function mutations in
the DNAI1 gene located on chromosome 9 was the first
genetic link to clinical PCD. Ciliary ultrastructure in that
patient showed an ODA defect in airway epithelial ciliary
structure. One of the mutations was a 4 base-pair (bp) in-
sertion causing a frameshift in exon 5, and leading to a pre-
mature translation termination. The mutation on the other
allele was a splice mutation (2193insT) of intron 1. This
mutation disrupts normal splicing, leading to the insertion
of 132-bp of intron 1 sequences in mRNA followed by
cryptic splice-donor site, which leads to the termination
signal at position 73 (9). Very recently Guichard and col-
leagues reported the same 2193insT mutation in five pa-
tients with PCD from three families (21). In the cohort of
patients and family members in the present study, the pre-
viously described 2193insT mutation was detected on one
allele in three PCD patients, belonging to two unrelated
families. The mutation on the second allele was W568S in
two patients (III-1 and III-3) from Family 5 and W568X in
the patient (II-2) from Family 16. All three patients have
disease typical of PCD, with recurrent sino-pulmonary dis-
Figure 4. Pedigrees demonstrating recessive
inheritance of the mutations. A novel mis-
sense mutation (W568S) was found in the af-
fected individuals (III-1 and III-3) from Fam-
ily 5, which was heterozygous 1874 G→C
transversion in exon 17. This mutation was
also found in the father, unaffected sibling,
paternal aunt, and paternal grandmother.
The previously reported splice mutation,
which was an insertion of a T at 3 position
of intron 1 (2193insT), was identified in
both the affected individuals. This mutation
was present in the mother, maternal aunt,
and maternal grandmother.
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ease, recurrent ear infections, with SI totalis in one. All three
are males; fertility status has not been established in the
younger patients (III-1 and III-3), though the spouse of
the adult male patient (II-2) achieved conception through
artificial insemination of his sperm, which is in accordance
with previous reports (22).
We identified two novel mutations at codon 568 in both
these families. The nonsense mutation (Family 16, W568X)
would presumably lead to a truncated protein, missing part
of exon 17 and exons 18–20. The allele frequency for this
mutation was 0.0025 (1 in 400 chromosomes) in non-PCD
individuals. The missense mutation (W568S; Family 5), af-
fected individuals (III-1, III-3) is likely to be a true genetic
mutation and not a polymorphism, since this mutation ap-
pears to occur at a very low gene frequency in the general
population. It is pertinent that both missense and non-
sense mutations occurred at the codon 568, which is con-
served residue in the protein. Hence, the DNA sequence
in that region is likely to be a hotspot for the mutations.
Further studies are needed to confirm this hypothesis. Our
findings are consistent with the autosomal recessive mode
of inheritance commonly reported in PCD families.
The PCD patients in this study had different mutations
on opposite alleles, and this compound heterozygous sta-
tus is consistent with the lack of consanguinity in these
families. The presence of the 2193insT mutation on one
allele in nine patients with PCD from six different families
(including the previous studies [9, 21]) indicates a rela-
tively high prevalence of 2193insT mutation. These ob-
servations suggest that this is either a common site for
spontaneous mutations, or the mutation could be the re-
sult of a founder effect. The data in this study are insuffi-
cient to differentiate between these possibilities, and fu-
ture studies will be necessary to answer this question.
In this study, the DNAI1 gene was not linked to the
PCD phenotype in five of seven unrelated families, based
on the results of intragenic SNPs and DNA sequencing.
This supports the earlier reports of locus heterogeneity for
the disease (9, 23). A locus on chromosome 5p has been
described in a large inbred Lebanese kindred with PCD
and defective ODA, using a homozygosity mapping strat-
egy (24), and DNAH5 (an axonemal heavy chain dynein)
is presumably a candidate gene. Another study provides
evidence for a PCD locus on chromosome 19q (between
the markers D19S572 and D19S218) in three Arab kin-
dred. This 15-cM critical region is gene rich, but a single
candidate gene is not yet defined (25).
The human DNAI1 gene encodes for a protein related
to an intermediate chain dynein, and is a member of the
axonemal protein family that exhibits evolutionary conser-
vation. The intermediate chains are involved in the assem-
bly of the outer arm complex (26, 27) and attachment to
the outer doublet microtubules, the process being ATP-
independent (28, 29). The DNAI1 gene is homologous
with sea urchin IC2 (GenBank accession no. D38538) and
Chlamydomonas reinhardtii IC78 (GenBank accession no.
U19120), and the IC78 gene was found to be deleted, or
disrupted by a large insertion, in an ODA-deficient mu-
tant of Chlamydomonas (30). The previous data and the
current findings support the hypothesis that the DNAI1
gene mutations will continue to be identified in patients
with PCD (9). Intermediate chain dyneins, including IC78,
are members of the WD family of proteins, which regulate
ciliary function via protein–protein interactions (30–33).
The crystal structure of WD containing G-
 transducin
(G
) protein (34) is a symmetrical structure made up of
repeats, which adopts a 
-propeller fold, each comprised
of a four-stranded antiparallel 
 sheet. Glycine-Histidine
and Tryptophan-Aspartate (GH-WD) flank the repeats.
Neither the GH nor the WD is absolutely conserved; the
aromatic amino acid W, which is also called a trademark
tryptophan, was found to be conserved only 79% of the
time (n  776 WD repeats analyzed), and 17% of the time,
it is replaced by other aromatic amino acids (phenylala-
nine and tyrosine). Both of the novel mutations (W568X
and W568S) occur at the same tryptophan residue. The re-
placement of a bulky aromatic W residue by serine (S)
may cause abnormal protein folding, since a bulky residue
is usually associated with the D to end the last strand of
the repeat and stabilize the folding of the turn between the
third and fourth strand. In other WD proteins, where this
W or aromatic amino acid is not conserved, S has not re-
placed it. All aligned WD repeats can be found at http://
bmerc-www.bu.edu/wdrepeat/.
In conclusion, we detected a previously described mu-
tation (2193insT) in the DNAI1 gene, and two novel mu-
tations in the same gene on the opposite allele in patients
with clinical and cell biologic evidence of PCD. Related
family members, including carriers of mutations in DNAI1
had no phenotypic expression of PCD-like disease. Utili-
zation of screening methods for rapid detection of the se-
quence variants at codon 568 and the 2193insT mutation
can expedite the process of mutation detection in PCD pa-
tients with ODA abnormalities. An increased understand-
ing of the underlying molecular and cell biologic mecha-
nisms will help in the development of more targeted therapies.
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